2188-18-3

Applied Filters:

Keyword:'2188-18-3'

Showing 1-1 of 1 result for "2188-18-3" within Papers

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

C Marzolini et al.

AIDS (London, England), 15(1), 71-75 (2001-02-24)

Limited information exists on the clinical usefulness of drug level monitoring for efavirenz, a once-daily non-nucleoside reverse transcriptase inhibitor (NNRTI). The aim of this study was to determine whether efavirenz plasma concentration monitoring could predict treatment failure and central nervous

Page 1 of 1